Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 9 studies | 23% ± 7% | |
epithelial cell | 6 studies | 29% ± 11% | |
CD8-positive, alpha-beta T cell | 4 studies | 23% ± 5% | |
fibroblast | 4 studies | 22% ± 4% | |
astrocyte | 4 studies | 20% ± 5% | |
CD8-positive, alpha-beta memory T cell | 4 studies | 18% ± 3% | |
CD4-positive, alpha-beta T cell | 3 studies | 24% ± 6% | |
pericyte | 3 studies | 20% ± 3% | |
lymphocyte | 3 studies | 21% ± 4% | |
GABAergic neuron | 3 studies | 38% ± 8% | |
glutamatergic neuron | 3 studies | 51% ± 11% | |
natural killer cell | 3 studies | 17% ± 2% | |
gamma-delta T cell | 3 studies | 30% ± 8% | |
basal cell | 3 studies | 27% ± 7% | |
transit amplifying cell | 3 studies | 27% ± 11% | |
interneuron | 3 studies | 34% ± 20% | |
neuron | 3 studies | 22% ± 4% | |
oligodendrocyte | 3 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3147.03 | 459 / 459 | 100% | 22.62 | 1118 / 1118 |
esophagus | 100% | 2796.28 | 1445 / 1445 | 100% | 21.88 | 183 / 183 |
lung | 100% | 2842.27 | 578 / 578 | 100% | 22.28 | 1155 / 1155 |
ovary | 100% | 4557.84 | 180 / 180 | 100% | 18.00 | 430 / 430 |
intestine | 100% | 3097.14 | 966 / 966 | 100% | 27.61 | 526 / 527 |
bladder | 100% | 3144.48 | 21 / 21 | 100% | 23.88 | 503 / 504 |
prostate | 100% | 3631.53 | 245 / 245 | 100% | 21.90 | 501 / 502 |
stomach | 100% | 2560.35 | 359 / 359 | 100% | 24.36 | 285 / 286 |
uterus | 100% | 4079.79 | 170 / 170 | 99% | 24.90 | 456 / 459 |
thymus | 100% | 3283.90 | 653 / 653 | 99% | 19.44 | 599 / 605 |
pancreas | 100% | 1962.74 | 328 / 328 | 99% | 17.79 | 176 / 178 |
brain | 98% | 1856.53 | 2586 / 2642 | 100% | 16.41 | 705 / 705 |
skin | 100% | 3323.09 | 1808 / 1809 | 98% | 20.28 | 462 / 472 |
adrenal gland | 100% | 3375.86 | 258 / 258 | 97% | 17.46 | 224 / 230 |
kidney | 100% | 2014.98 | 89 / 89 | 97% | 13.85 | 877 / 901 |
liver | 100% | 1625.67 | 226 / 226 | 95% | 11.01 | 384 / 406 |
adipose | 100% | 2936.36 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3028.79 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 21.96 | 29 / 29 |
spleen | 100% | 3205.64 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 15.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.15 | 1 / 1 |
muscle | 100% | 1985.70 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 2655.42 | 852 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 15.63 | 76 / 80 |
peripheral blood | 77% | 1455.71 | 718 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043488 | Biological process | regulation of mRNA stability |
GO_2000117 | Biological process | negative regulation of cysteine-type endopeptidase activity |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0045579 | Biological process | positive regulation of B cell differentiation |
GO_0048536 | Biological process | spleen development |
GO_0070828 | Biological process | heterochromatin organization |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0090267 | Biological process | positive regulation of mitotic cell cycle spindle assembly checkpoint |
GO_0015031 | Biological process | protein transport |
GO_0000973 | Biological process | post-transcriptional tethering of RNA polymerase II gene DNA at nuclear periphery |
GO_0016973 | Biological process | poly(A)+ mRNA export from nucleus |
GO_1905457 | Biological process | negative regulation of lymphoid progenitor cell differentiation |
GO_0060633 | Biological process | negative regulation of transcription initiation by RNA polymerase II |
GO_0005634 | Cellular component | nucleus |
GO_0070390 | Cellular component | transcription export complex 2 |
GO_0044615 | Cellular component | nuclear pore nuclear basket |
GO_0005737 | Cellular component | cytoplasm |
GO_0003690 | Molecular function | double-stranded DNA binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PCID2 |
Protein name | PCI domain-containing protein 2 (CSN12-like protein) HCG2012301 (PCID2 protein) |
Synonyms | HT004 hCG_2012301 |
Description | FUNCTION: Required for B-cell survival through the regulation of the expression of cell-cycle checkpoint MAD2L1 protein during B cell differentiation (By similarity). As a component of the TREX-2 complex, involved in the export of mRNAs to the cytoplasm through the nuclear pores . Binds and stabilizes BRCA2 and is thus involved in the control of R-loop-associated DNA damage and transcription-associated genomic instability . Blocks the activity of the SRCAP chromatin remodeling complex by interacting with SRCAP complex member ZNHIT1 and inhibiting its interaction with the complex (By similarity). This prevents the deposition of histone variant H2AZ1/H2A.Z at the nucleosomes of key lymphoid fate regulator genes which suppresses their expression and restricts lymphoid lineage commitment (By similarity). . |
Accessions | ENST00000375459.5 [Q5JVF3-2] ENST00000375479.6 [Q5JVF3-1] ENST00000622406.4 [Q5JVF3-4] ENST00000375477.5 [Q5JVF3-1] Q5JVF3 ENST00000246505.9 [Q5JVF3-4] ENST00000337344.9 [Q5JVF3-1] ENST00000375457.2 [Q5JVF3-2] Q96H21 |